The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 881-890

  Hansson, Emma K ^a   Friberg, Lena E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Febrile neutropenia; Haematological toxicity; NONMEM; Oncology

Indexed keywords

CAPECITABINE; DOCETAXEL; HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG HALF LIFE; DRUG SENSITIVITY; FEBRILE NEUTROPENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FEVER; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPENIA; RISK FACTORS; TAXOIDS;

EID: 84859790996     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1769-7     Document Type: Article

References (46)

1. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia - risks, consequences, and new directions for its management. Cancer 100(2):228-237 (Pubitemid 38063629)
2. National Cancer Institute, National (2006) Common terminology criteria for adverse events v3.0. Available at http://www.eortc.be/services/doc/ctc/ ctcaev3.pdf
3. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258-2266 (Pubitemid 43673249)
4. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JAH, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427-431
5. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EO-RTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8-32
6. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P (2005) 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. Br Med J 330(7485):217-220 (Pubitemid 40188068)
7. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90(16):1205-1211 (Pubitemid 28407086)
8. Mayers C, Panzarella T, Tannock IF (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91(12):2246-2257 (Pubitemid 32552809)
9. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80(11):1763-1766 (Pubitemid 29389629)
10. Cameron DA, Massie C, Kerr G, Leonard RCF (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89(10):1837-1842 (Pubitemid 37533256)
11. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75(2):301-305 (Pubitemid 27019578)
12. Pascoe J, Cullen M (2006) The prevention of febrile neutropenia. Curr Opin Oncol 18(4):325-329 (Pubitemid 44297241)
13. Timmer-Bonte JNH, Tjan-Heijnen VCG (2006) Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Anticancer Drugs 17(8):881-889 (Pubitemid 44350607)
14. Wingard JR, Elmongy M (2009) Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 72(2):144-154
15. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187-3205 (Pubitemid 46638957)
16. Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10(6):427-437 (Pubitemid 40993570)
17. Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9):1917-1927. doi:10.1002/cncr.25691
18. Bodey GP, Buckley M, Sathe YS, Freireic EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328-340
19. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713-4721 (Pubitemid 36025290)
20. Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23(3):413-421 (Pubitemid 46224216)
21. Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58(2):143-156
22. Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, Peraire C, Obach R (2006) Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57(6):727-735
23. Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567-578 (Pubitemid 39601546)
24. Latz J, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57(4):412-426 (Pubitemid 43087584)
25. Hansson EK, Wallin JE, Lindman H, Sandstrom M, Karlsson MO, Friberg LE (2010) Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 65(5):839-848
26. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12(18):5481-5490 (Pubitemid 44497264)
27. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812-2823 (Pubitemid 34651510)
28. Beal S, Sheiner L, Boekmann A, Bauer RJ (2009) NONMEM user's guides (1989-2006). Icon Development Solutions, Ellicott City
29. Lindbom L, Ribbing J, Jonsson EN (2004) Perls-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85-94 (Pubitemid 38798039)
30. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 80(3):241-257 (Pubitemid 41196689)
31. Jonsson EN, Karlsson MO (1999) Xpose:an Splus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64 (Pubitemid 29049052)
32. Bruno R, Vivier N, Vergniol JC, DePhillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere(R)): model building and validation. J Pharmacokinet Biopharm 24(2):153-172 (Pubitemid 26300483)
33. Karlsson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population-model for the leukopenic effect of etoposide. Clin Pharmacol Ther 55(2):325-335
34. Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ (2000) Models of schedule dependent haematological toxicity of 2′-deoxy-2′- methylidenecytidine (DMDC). Eur J Clin Pharmacol 56(8):567-574
35. Cartwright GE, Athens JW, Wintrobe MM (1964) The kinetics of granulopoiesis in normal man. Blood 24(6):780-803
36. Karlsson MO, Holford NHG (2008) A tutorial on visual predictive checks, p 17, Abstr 1434. http://wwwpage-meetingorg/?abstract=1434
37. Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30(6):387-404 (Pubitemid 38221931)
38. Bergstrand M, Hooker AC, Karlsson MO (2009) Visual predictive checks for censored and categorical data, p 18, Abstr 1604. http://wwwpage-meetingorg/? abstract=1604
39. Bruno R, Hille D, Riva A, Vivier N, Huinnink W, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravclin PM, Sheiner LB (1998) Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187-196 (Pubitemid 28041598)
40. Ozawa K, Minami H, Sato H (2008) Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. Cancer Chemother Pharmacol 62(3):551-557
41. Valero V (1997) Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24(4):S11-S18
42. Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOPR, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98(11):2402-2409 (Pubitemid 37466655)
43. Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6(2):109-118 (Pubitemid 351340522)
44. Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97(3):290-296 (Pubitemid 47196745)
45. Wallin J, Friberg LE, Karlsson MO (2010) Model-based neutrophil guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol 106(3):234-242
46. Wallin J, Friberg LE, Karlsson MO (2009) A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed 93(13):283-291